Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen

Hum Cell. 2005 Mar;18(1):17-23. doi: 10.1111/j.1749-0774.2005.tb00053.x.

Abstract

Prostate cancer cells express prostate-specific membrane antigen (PSMA). We developed an IgM type monoclonal antibody against PSMA. The antibody was coupled to poly-L-lysine and thereafter this conjugate was mixed with cationic liposomes containing plasmid DNA. The antibody-liposome complex was tested whether it could deliver the gene of interest selectively to the PSMA positive cells. As assessed by beta-galactosidase reporter gene, the transfection efficiency was 13.2% with anti-PSMA-liposome complex as compared to 4% with control IgM liposome complex. In contrast, no such differences were observed in PSMA negative PC-3, DU145 and T24 cells. Furthermore, in the suicide gene therapy in vitro with thymidine kinase gene plus ganciclovir system, anti-PSMA liposome complex demonstrated a selective growth inhibitory effect on PSMA positive LNCaP cells but not on PSMA negative cell lines.

MeSH terms

  • Adenocarcinoma / therapy*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / metabolism
  • DNA
  • Gene Targeting
  • Genes, Transgenic, Suicide
  • Genetic Therapy / methods*
  • Humans
  • Immunoglobulin M / administration & dosage*
  • Immunoglobulin M / metabolism
  • Liposomes
  • Male
  • Plasmids / genetics
  • Prostate-Specific Antigen / immunology*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / therapy*
  • Transfection
  • Tumor Cells, Cultured

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin M
  • Liposomes
  • DNA
  • Prostate-Specific Antigen